Latest Whitepapers

Immunotherapy has the potential to treat a wide variety of conditions, from autoimmune disease to cancer. However, the discovery of potential antibody therapeutics against key receptor proteins remains a major challenge for the traditional immunisation approaches currently available on the market.

Currently, various treatments are available to cancer patients, such as chemotherapy, targeted therapy and immunotherapy. Targeted therapy is a type of precision medicine that targets the proteins that control the growth, division and spread of cancer cells.

Download your whitepaper to learn more about modeling COVID-19 infection in organoids, how to combat COVID-19 variants as well as the future of organoid technology.

Liquid biopsies are rapidly gaining traction and becoming a standard of care for cancer. They are an attractive alternative to invasive, painful, costly tissue biopsies and can facilitate real-time monitoring while providing insight into the disease state, even for tissues that are difficult to access, such as brain cancers.

Cancer immunotherapy relies on activating or enhancing the antitumor immune response and has taken a central position in cancer treatment modalities. However, not all patients respond to immunotherapy, and combination immunotherapies increase cost of treatment and heighten the risk for toxicity-related adverse events.

Immuno-oncology research investigates how the immune system interacts with cancer cells within the tumor microenvironment, a process which is not fully understood.

With recent advances in cancer detection and prevention, a future where cancer can be cured is starting to feel within reach. One significant area of progress is early detection, which can go a long way toward eliminating cancer.

The successful use of immunotherapies to help combat cancer has expanded rapidly in the last few years, with many therapies now approved for clinical use.

As we have gained a greater understanding of cancer biology, therapeutic interventions have evolved from a one-size-fits-all approach to more targeted approaches, which afford patients not only longer lives but increased quality of life.

Cell-based chimeric antigen receptor (CAR) T-cell therapies have rapidly advanced from preclinical research. This success has driven an influx of companies to further develop CAR T-cell constructs to make them more effective, safe and persistent.